ThromboGenics Starts Phase II Trial for Macular Degeneration Therapy

ThromboGenics, a company specializing in biotherapeutics for vascular diseases, cancer, and eye diseases, has announced the start of a Phase II trial of microplasmin to treat age-related wet macular degeneration (AMD).

Read more »

Cytori’s (NASDAQ: CYTX) Natural Celution for Breast Reconstruction

Cytori Therapeutics is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types.

Read more »

[Company Profile] Stentys

Medical device company Stentys seeks to correct the problem of poor apposition with its self-expanding stent technology.

Read more »

Bioguard Wound Dressings Beat Swine Flu In Independent Study

Derma Sciences, a developer of wound care products, announced that its Bioguard Barrier Dressings effectively safeguarded against the H1N1 “swine flu” virus in an independent laboratory study.

Read more »

Celgene Acquires Gloucester In $340M Deal

Biopharmaceutical company Celgene is plumping up its oncology pipeline with its latest acquisition.

Read more »

Vertex to Sell 1.5 Million Shares

Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.

Read more »

Hope for Epilepsy Patients, But Treatment Gap Exists Worldwide

An exciting discovery may change the way epilepsy is treated, but if current evidence is any indication, getting the treatment to patients will be a challenge.

Read more »

Potential Hepatitis C Breakthrough for Santaris

In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.

Read more »

FDA Approves Treatment for Rare Swelling Disease

Biopharmaceutical company Dyax Corporation has received regulatory approval to market its drug ecallantide (Kalbitor) for a rare genetic disorder called hereditary angioedema (HAE).

Read more »

Provectus Reports Positive Preliminary Data for Dermatology Drug

Patients with psoriasis demonstrated 79% improvement in the Psoriasis Scoring Index after four weeks of daily treatment with PH-10.

Read more »